1. Nucleic acid-based therapies have the potential to treat a wide range of diseases.
2. Cell-penetrating peptides (CPPs) are gaining interest as delivery systems for therapeutic nucleic acids (NAs).
3. Peptide-based nanoparticles (PBNs) can be used to deliver NAs in vitro and in vivo, with defined formulation conditions to obtain PBNs of 60 nm to 150 nm with a homogeneous dispersity and a positive charge between +10 mV and +40 mV.
The article “Peptide-Based Nanoparticles for Therapeutic Nucleic Acid Delivery” is an informative review of the use of peptide-based nanoparticles for therapeutic nucleic acid delivery. The article provides an overview of the current state of research on this topic, including the most relevant peptides or peptide families forming PBNs in the presence of NAs described since 2015, as well as biophysical and biological aspects related to non-viral peptide-based nanoparticles for therapeutic nucleic acid formulations as a delivery system.
The article is written in an objective manner, presenting both sides equally and providing evidence for its claims. It does not contain any promotional content or partiality towards any particular viewpoint or opinion. The authors also note possible risks associated with using these types of delivery systems, such as toxicity issues that may arise from using certain peptides or nanocomplexes. Furthermore, all sources used by the authors are reliable and trustworthy, making this article a reliable source of information on this topic.
In conclusion, this article is written in an unbiased manner and provides reliable information on the use of peptide-based nanoparticles for therapeutic nucleic acid delivery.